ALGS Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 May 2024 @ 16:00):

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases...

Stats
Today's Volume	185 308
Average Volume	402 233
Market Cap	63.28M
EPS	$-0.220 ( 2024-05-02 )
Next earnings date	( $-0.190 ) 2024-06-27
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.600
ATR14	$0.00800 (0.99%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-01	Mcclure Matthew W.	Buy	72 000	Stock Option (Right to Buy)
2024-03-01	Calhoun Lesley Ann	Buy	308 940	Stock Option (Right to Buy)
2024-03-01	Symons Julian A.	Buy	72 000	Stock Option (Right to Buy)
2024-03-01	Blatt Lawrence	Buy	965 435	Stock Option (Right to Buy)
2024-02-28	Hirth Peter	Buy	4 411	Stock Option (Right to Buy)

INSIDER POWER
82.23
Last 96 transactions
Buy: 18 924 669 \| Sell: 1 675 487

Volume Correlation

Long: 0.20 (neutral)

Short: 0.99 (very strong)

Signal:(49.386) Expect same movement, but be aware

Aligos Therapeutics, Inc. Correlation

10 Most Positive Correlations
MCRB	0.914
EIGR	0.914
SPRC	0.908
BTTX	0.907
ENTA	0.907
AFIB	0.906
CYN	0.906
CAMP	0.905
MESA	0.904
GOCO	0.904

10 Most Negative Correlations
GEEX	-0.92
FXCO	-0.918
LDHA	-0.917
NESR	-0.914
TCVA	-0.911
ALOR	-0.911
TBSA	-0.909
VLAT	-0.909
AHRN	-0.908
LGAC	-0.908

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Aligos Therapeutics, Inc. Correlation - Currency/Commodity

0.51
( weak )

0.22
( neutral )

0.00
( neutral )

0.59
( weak )

0.00
( neutral )

0.12
( neutral )

Aligos Therapeutics, Inc. Financials

Annual	2023
Revenue:	$15.53M
Gross Profit:	$12.46M (80.24 %)
EPS:	$-1.360

FY	2023
Revenue:	$15.53M
Gross Profit:	$12.46M (80.24 %)
EPS:	$-1.360

FY	2022
Revenue:	$13.91M
Gross Profit:	$10.23M (73.57 %)
EPS:	$-2.25

FY	2021
Revenue:	$4.36M
Gross Profit:	$4.36M (100.00 %)
EPS:	$-3.22

Financial Reports:

No articles found.

Aligos Therapeutics, Inc.

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California.